Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease - Concepedia

Concepedia

Publication | Open Access

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

DOI Full Paper Access

405

Citations

14

References

2013

Year

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul, Philippe Agapé, Franck E. Nicolini, Bruno Varet, Martine Gardembas, Gabriel Étienne, Delphine Réa, Lydia Roy,

Journal of Clinical Oncology

Abstract

Loss of MMR is a practical and safe criterion for restarting therapy in patients with CML with prolonged CMR.

References

	Year	Citations

Page 1